2004-06-08-世界卫生组织-INN_Proposed_List_91_46页_355kb

Summary of Proposed and Recommended International Nonproprietary Names for Pharmaceutical Substances (INN)

Core Content

The document outlines the process and information related to the proposed and recommended International Nonproprietary Names (INNs) for pharmaceutical substances, specifically focusing on List 91 of Proposed INNs and related data. These names are considered by the World Health Organization (WHO) for international standardization of drug nomenclature, but their inclusion does not imply any recommendation for medical or pharmaceutical use.

Main Points

• INN Purpose: INNs are used to provide a standardized, non-proprietary name for pharmaceutical substances, facilitating global communication and understanding in medicine and pharmacy.
• Proposed INN Status: The names in the Proposed INN lists are under review and are not yet officially recommended. They are provisional and may not be included in the Cumulative Lists of INNs.
• Comments and Objections: Any person may submit comments or formal objections to the proposed names within four months of their publication in WHO Drug Information.
• Deadline for List 91: For the List 91 Proposed INN, the deadline is 15 December 2004.
• Language Variations: The names are provided in Latin, English, French, and Spanish to ensure international accessibility.
• Chemical Information: Each proposed name includes the chemical name, action and use, molecular formula, CAS registry number, and graphic formula.
• Provisional Nature: The WHO does not endorse or comment on the efficacy or use of the substances. The descriptors are not revised and are not included in the official Cumulative Lists of INNs.

Key Information

Proposed INN: abataceptum

• Chemical Name: 1-25-oncostatin M (human precursor) fusion protein with CTLA-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimolecular (146→146')-disulfide immunomodulator
• Action and Use: Immunomodulator
• Molecular Formula: $\mathrm{C_{4490}H_{6823}N_{1197}O_{1298}S_{32}}$
• CAS Registry Number: 506433-25-6

Proposed INN: acotiamidum

• Chemical Name: N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]thiazol-4-carboxamide
• Action and Use: Antiemetic (parasympathomimetic)
• Molecular Formula: $\mathrm{C_{21}H_{30}N_{4}O_{5}S}$
• CAS Registry Number: 185106-16-5

Proposed INN: alagebrium chloride

• Chemical Name: 4,5-dimethyl-3-(2-oxo-2-phenylethyl)thiazolium chloride
• Action and Use: Agent influencing protein glycosylation
• Molecular Formula: $\mathrm{C_{13}H_{14}ClNOS}$
• CAS Registry Number: 341028-37-3

Proposed INN: daxalipramum

• Chemical Name: (5R)-5-(4-methoxy-3-propoxyphenyl)-5-methyl-1,3-oxazolidin-2-one
• Action and Use: Phosphodiesterase IV inhibitor
• Molecular Formula: $\mathrm{C_{14}H_{19}NO_{4}}$
• CAS Registry Number: 189940-24-7

Proposed INN: fidexabanum

• Chemical Name: [2-(5-carbamimidoyl-2-hydroxyphenoxy)-3,5-difluoro-6-[3-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]methylamino} = acetic acid
• Action and Use: Blood coagulation factor Xa inhibitor
• Molecular Formula: $\mathrm{C_{25}H_{24}F_{2}N_{6}O_{5}}$
• CAS Registry Number: 183305-24-0

Proposed INN: fingolimodum

• Chemical Name: 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
• Action and Use: Immunomodulator
• Molecular Formula: $\mathrm{C_{19}H_{33}NO_{2}}$
• CAS Registry Number: 162359-55-9

Proposed INN: golimumabum

• Chemical Name: Immunoglobulin G1, anti-(human tumor necrosis factor α) (human monoclonal CNTO 148 γ1-chain), disulfide with human monoclonal CNTO 148 κ-chain, dimer
• Action and Use: Immunomodulator
• Molecular Formula: $\mathrm{C_{6530}H_{10068}N_{1752}O_{2026}S_{44}}$
• CAS Registry Number: 476181-74-5

Proposed INN: indibulinum

• Chemical Name: 2-[1-(4-chlorophenylmethyl)-1H-indol-3-yl]-2-oxo-N-(pyridin-4-yl)acetamide
• Action and Use: Antineoplastic agent
• Molecular Formula: $\mathrm{C_{22}H_{16}CIN_{3}O_{2}}$
• CAS Registry Number: 204205-90-3

Proposed INN: ismomultinum alfa

• Chemical Name: 47-261-Glycoprotein gp 39 (human clone CDM8-gp39 reduced)
• Action and Use: Antirheumatic
• Molecular Formula: $\mathrm{C_{1827}H_{2785}N_{493}O_{530}S_{11}}$
• CAS Registry Number: 457913-93-8

Proposed INN: Iestaurtinib

• Chemical Name: (9S,10S,12R)-10-hydroxy-10-(hydroxymethyl)-9-methyl-2,3,9,10,11,12-hexahydro-1H-9,12-epoxydiindolo=[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one
• Action and Use: Antineoplastic agent
• Molecular Formula: $\mathrm{C_{26}H_{21}N_{3}O_{4}}$
• CAS Registry Number: 111358-88-4

Proposed INN: libivirumabum

• Chemical Name: Immunoglobulin G, anti-(hepatitis B surface antigen) (human monoclonal 17.1.41 heavy chain), disulfide with human monoclonal 17.1.41 κ-chain, dimer
• Action and Use: Antiviral
• Molecular Formula: $\mathrm{C_{6416}H_{9924}N_{165}O_{213}S_{44}}$
• CAS Registry Number: 544697-52-1

Notes

• Glycosylation Sites: Some entries include specific glycosylation sites, indicating structural features relevant to the molecule.
• Chemical Structures: Graphic formulas are included for some substances, though not all.
• Language Consistency: The document provides translations of the INNs in Latin, English, French, and Spanish, ensuring accessibility across languages.
• Provisional Descriptors: These names are not final and are subject to review. They do not appear in the official Cumulative Lists of INNs.